Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) announced that its Group One first-in-human clinical patients have reached the 12-month follow-up milestone in the development program for its accommodating intraocular lens, known as the Ocumetics Lens. The company reports a progression of encouraging clinical observations across the one-, three-, and six-month follow-up visits, including one previously legally blind patient who achieved vision qualifying them to drive. Full 12-month results are described as forthcoming, and the company states it is preparing to advance to its Group Two patient cohort.

Key Points

  • Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) is a Calgary-based ophthalmic lens developer
  • Group One first-in-human patients have reached the 12-month follow-up milestone in the Ocumetics Lens clinical program
  • All Group One patients achieved distance vision of 20/40 or better at approximately one month post-surgery
  • Investors may be watching for the formal 12-month data release and progress on Group Two patient surgeries

Group One Visual Outcomes Across One, Three, and Six Months

The announcement details a staged progression of clinical results. At approximately one month following surgery, all Group One patients achieved distance vision of 20/40 or better, representing meaningful functional improvement for participants who entered the study with significant visual impairment. By three months, results met or exceeded the company's predefined internal benchmarks for safety, lens delivery, and foundational distance vision performance. At six months, visual outcomes continued to improve and the safety profile remained encouraging, with the company stating these results supported its decision to advance the clinical development program.

Patient Quality-of-Life Reports at the Six-Month Mark

Beyond clinical measurements, the company highlights patient-reported quality-of-life improvements observed at the six-month follow-up. The release states patients described an improved ability to read, watch television, recognise family members, and participate in everyday activities with greater visual independence. Notably, one patient who entered the study as legally blind is reported to have achieved vision that qualified them to drive. Ocumetics emphasises these experiences reflect the potential real-world impact of the lens technology, while noting these remain early first-in-human results that should not be interpreted as established proof of safety or efficacy.

Twelve-Month Examinations Commenced and Group Two Advancement Planned

Group One patients have commenced their 12-month follow-up examinations, which the company describes as an important step for assessing the durability of visual outcomes and the ongoing safety and performance of the Ocumetics Lens. Ocumetics states it will report appropriate clinical information as it becomes available. The company also disclosed it is preparing to advance to Group Two surgeries, which — unlike Group One's sole focus on safety — are designed to study safety alongside both distance and near vision performance of the Ocumetics Lens. Additional clinical data and regulatory evaluation will be required as the program advances.